Personalis Inc (NASDAQ:PSNL) — Market Cap & Net Worth
Market Cap & Net Worth: Personalis Inc (PSNL)
Personalis Inc (NASDAQ:PSNL) has a market capitalization of $626.23 Million ($626.23 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11288 globally and #2844 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Personalis Inc's stock price $9.75 by its total outstanding shares 104721098 (104.72 Million). Review Personalis Inc total liabilities to assess the company's total debt and financial obligations.
Personalis Inc Market Cap History: 2019 to 2026
Personalis Inc's market capitalization history from 2019 to 2026. Data shows change from $1.14 Billion to $1.02 Billion (-14.21% CAGR).
Index Memberships
Personalis Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.03% | #299 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1117 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.04% | #175 of 263 |
Weight: Personalis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Personalis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Personalis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.97x
Personalis Inc's market cap is 11.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.14 Billion | $65.21 Million | -$25.08 Million | 17.51x | N/A |
| 2020 | $3.83 Billion | $78.65 Million | -$41.28 Million | 48.75x | N/A |
| 2021 | $1.49 Billion | $85.49 Million | -$65.23 Million | 17.48x | N/A |
| 2022 | $207.35 Million | $65.05 Million | -$113.31 Million | 3.19x | N/A |
| 2023 | $219.91 Million | $73.48 Million | -$108.30 Million | 2.99x | N/A |
| 2024 | $605.29 Million | $84.61 Million | -$81.28 Million | 7.15x | N/A |
| 2025 | $833.58 Million | $69.65 Million | -$81.27 Million | 11.97x | N/A |
Competitor Companies of PSNL by Market Capitalization
Companies near Personalis Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Personalis Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $173.46 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.56 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #640 globally with a market cap of $43.08 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $173.46 Billion | $461.69 |
| #189 | Danaher Corporation | NYSE:DHR | $125.56 Billion | $177.76 |
| #640 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.08 Billion | $546.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Personalis Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Personalis Inc's market cap moved from $1.14 Billion to $ 1.02 Billion, with a yearly change of -14.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.02 Billion | +22.49% |
| 2025 | $833.58 Million | +37.72% |
| 2024 | $605.29 Million | +175.24% |
| 2023 | $219.91 Million | +6.06% |
| 2022 | $207.35 Million | -86.12% |
| 2021 | $1.49 Billion | -61.02% |
| 2020 | $3.83 Billion | +235.87% |
| 2019 | $1.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Personalis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $626.23 Million USD |
| MoneyControl | $626.23 Million USD |
| MarketWatch | $626.23 Million USD |
| marketcap.company | $626.23 Million USD |
| Reuters | $626.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole tran… Read more